Article in Pharmaceutical research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 5 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors at 2 institutions in 4 countries.
Hovhannes J GukasyanDepartment of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, California, USA.
Tomomi UchiyamaDepartment of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, California, USA.
Kwang-Jin KimDepartment of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, California, USA.ORCID http://orcid.org/0000-0001-7547-1681
Carsten EhrhardtSchool of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin 2, Ireland.
Sharon K WuDepartment of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, California, USA.
Zea BorokWill Rogers Institute Pulmonary Research Center, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.ORCID http://orcid.org/0000-0001-8673-8177
Edward D CrandallWill Rogers Institute Pulmonary Research Center, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Vincent H L LeeDepartment of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, California, USA. vincent.lee@cuhk.edu.hk.ORCID http://orcid.org/0000-0001-7708-6269
University of Southern California · USTrinity College Dublin · IE
Funding
ABSORPTION MECHANISMS FOR PEPTIDE/PROTEIN DRUGS VIA LUNGR01HL064365 · NHLBI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI CRANDALL, EDWARD DAVID · 1999 to 2008
$6.3M
Role of ATI cells in alveolar epithelial ion transportR01HL038621 · NHLBI · WEILL MEDICAL COLLEGE OF CORNELL UNIV · PI CRANDALL, EDWARD DAVID · 1986 to 2010
$3.2M
Mechanisms of beta-catenin signaling in alveolar epithelial cell differentiationR01HL112638 · NHLBI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BOROK, ZEA, KAHN, MICHAEL · 2013 to 2016
$2.2M
REGULATION OF ALVEOLAR EPITHELIAL CELL DIFFERENTIATIONR01HL038578 · NHLBI · WEILL MEDICAL COLLEGE OF CORNELL UNIV · PI BOROK, ZEA · 1986 to 2007
$1.7M
Regulation of lung alveolar epithelial protein transportR01HL038658 · NHLBI · WEILL MEDICAL COLLEGE OF CORNELL UNIV · PI KIM, KWANG-JIN · 1989 to 2005
$1.4M
PEPT1: STRUCTURE-FUNCTION, SORTING AND MODULATIONR01GM059297 · NIGMS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HAWORTH, IAN S · 2000 to 2003
$1.3M
Monocyte P311 Expression Level as Predictor of Hypertension in MiceRC1HL099504 · NHLBI · UNIVERSITY OF CHICAGO · PI SCHUGER, LUCIA · 2009 to 2010
$972k
Role of claudin 18 in regulation of lung stem/progenitor cell homeostasisR01HL126877 · NHLBI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BOROK, ZEA · 2016 to 2017
$587k
LUNG EPITHELIAL TRANSPORT PROPERTIES AND ALVEOLAR EDEMAR37HL038578 · NHLBI · WEILL MEDICAL COLLEGE OF CORNELL UNIV · PI CRANDALL, EDWARD DAVID · 1987 to 1996
purposeStudies were conducted in primary cultured rat alveolar epithelial cell monolayers to characterize peptide transporter expression and function.
methodsFreshly isolated rat lung alveolar epithelial cells were purified and cultured on permeable support with and without keratinocyte growth factor (KGF). Messenger RNA and protein expression of Pept1 and Pept2 in alveolar epithelial type I- and type II-like cell monolayers (±KGF, resp.) were examined by RT-PCR and Western blotting.
resultsRT-PCR showed expression of Pept2, but not Pept1, mRNA in both cell types. Western blot analysis revealed presence of Pept2 protein in type II-like cells, and less in type I-like cells. Bi-directional transmonolayer
conclusionsThis study confirms the absence of Pept1 from rat lung alveolar epithelium in vitro. Functional Pept2 expression in type II-like cell monolayers suggests its involvement in oligopeptide lung disposition, and offers rationale for therapeutic development of di/tripeptides, peptidomimetics employing pulmonary drug delivery.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Oligopeptide Transport in Rat Lung Alveolar Epithelial Cells is Mediated by Pept2. · full record | OpenQuestion